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Tamoxifen is a selective oestrogen receptor modulator used in pre-menopausal oestrogen receptor
positive breast cancer patients as adjuvant endocrine treatment. Increased risk of venous thrombo-
embolism with the use of Tamoxifen is well known from published literature. This risk further
increases in patients undergoing surgical procedures of high risk involving prolonged period of immo-
bilization, therefore withholding Tamoxifen treatment in the immediate peri-operative period should be
considered as a risk reducing measure. In the absence of nationally agreed guidelines on the safe
duration for stoppage of treatment in the pre and post operative period without worsening cancer
prognosis, operating surgeons and individual trusts have adopted their own guidelines based on indi-
vidual experience. From the available evidence in the literature on the VTE risk assessments based on
age, operative procedure and pharmacokinetics of the Tamoxifen drug we would like to propose
a working algorithm for selecting the right patient group and safe treatment stoppage durations. These
proposed guidelines are formulated taking all the risk factors of VTE, operative risks, pharmacokinetics of
the drug and chemotherapy risks into consideration. With this guidance, we aim to help surgeons across
different specialities in the decision making process through a structured evidence based approach.
 2012 Surgical Associates Ltd. Published by Elsevier Ltd. All rights reserved.1. Introduction
Tamoxifen is an oestrogen receptor modulator, selectively
binding and antagonising oestrogen effects. Tamoxifen is routinely
used in oestrogen receptor (ER) positive breast cancers as adjuvant
endocrine therapy post surgery in pre-menopausal women.
Increased risk of venous thrombo-embolism (VTE) associated with
tamoxifen treatment is well known from various studies.1e4 The
International Breast Cancer Intervention Study (IBIS) and European
Institute of Oncology trials have shown a 2.3 fold increased risk of
venous thrombo-embolism in women treated with tamoxifen
compared to placebo.5 Other associated independent factors such
as obesity, atherosclerosis, factor V Leiden6,7 prothrombinmutation
and smoking further increase the risk of Tamoxifen induced
VTE.Fig. 1
A search for evidence based guidelines on stoppage duration of
Tamoxifen in breast cancer patients during the perioperative period
to reduce the risk of VTE was carried out from Pub Med and
MEDLINE databases. Search terms like “guidelines on Tamoxifen
stoppage in perioperative period”, “Tamoxifen stoppage durationussain).
ciates Ltd. Published by Elsevier Ltand postoperative VTE incidence” and “Tamoxifen and duration of
surgery” showed no previous publications on the related topic.
2. Aim
To establish an algorithm for patient selection and safe stoppage
duration of Tamoxifen treatment pre-operatively in breast cancer
patients undergoing surgical interventions.
Our proposed algorithm is derived in the light of the clinical
evidence of increased risk of VTE with different surgical procedures
and individual risk factors; along with these, recent chemotherapy
treatment and duration of surgical procedure have also been
considered.
3. Evidence on perioperative VTE risk
The risk of VTE is increased by having cancer; studies have
shown a 4-fold increased risk of VTE average across all the cancers
with an annual reported incidence of approximately 0.48%. This risk
is increased further in patients having surgery immediately after
ﬁnishing breast chemotherapy,8 with an overall estimated risk of
0.16% within 60 days after the procedure. Data from the large
prospective cohort study “The Million Women Study”9 indicated “ad. All rights reserved.
Fig. 1. Flow chart of the Peri-operative Tamoxifen stoppage guidance * 3 weeks stoppage time decided based on pharmacokinetics of the drug tamoxifen, >90% cleared from plasma
within 3 weeks. Peak plasma concentration is reached within 2 weeks of restarting Tamoxifen. Risk of VTE after surgery is substantially high in ﬁrst 6 weeks after an inpatient
operation, BMJ. 2009 Dec 3; 339:b4583.
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operations and 6 weeks after day-surgery”. This risk was found to
be highest for joint replacement and cancer surgery. The overall
risk conclusions from this study showed an increase of 70 and 10
fold following in-patient and day-surgeries in comparison to
women not having any surgery during the study period.
Evidence for continuing VTE prophylaxis (Mechanical and
Pharmacological) after surgery in cancer patients comes from
National Institute of Clinical Evidence (NICE).14 It can be adopted for
both day-case and in-patient surgery carried out under General
Anaesthesia (GA). Pharmacological prophylaxis using “Low
Molecular Weight Heparin (LMWH) should continued until the
patient’s mobility is no longer signiﬁcantly impaired in the absence
of any major risks of bleeding from surgery.” This time period is
about 5e7 days. Extended pharmacological prophylaxis for 28 days
is recommended after major cancer surgery in the abdomen and
pelvis. Surgical procedures performed under Local Anaesthesia do
not need any VTE prophylaxis in the absence of impaired mobility
even in the cancer patients.
3.1. Correlation between tamoxifen and VTE incidence after surgery
The only published evidence to date on the incidence rates of
VTE after breast surgery comes from the NHS hospital episode
statistics database15 from year 2004, this data holds the record of
every patient admitted to NHS hospital in England with secondary
symptomatic deep vein thrombosis or pulmonary embolisms
following various surgical procedures. Summarized below (Table 1)are the results from total of 22 episodes in a sample size of 78,547
patients recorded, accounting for an overall risk of 0.03%. Patient
groups included in the registry have been mentioned to have
received some form of thrombo prophylaxis following surgical
procedures; with no deﬁnite details on type and duration of
thrombo prophylaxis mentioned.
The risk of VTE increases signiﬁcantly in breast cancer patients
following any surgical procedure if patients had been on recent
chemotherapy or using Tamoxifen for long. This risk was found to
be 0.8% within 6 weeks of surgery after breast chemotherapy from
the Clahsen et al. study group,10 part of the European Organization
for Research and Treatment of Cancer (EORTC) adjuvant breast
cancer therapy trial. Kirwin et al.11 explained this increased risk in
breast cancer patients post chemotherapy treatment to an increase
level of serum and platelet released vascular endothelial growth
factor (VEGF). This response was measured at different time
intervals after commencement of treatment and was believed to be
secondary to chemotherapy induced angiogenic response.
Further evidence supporting an increase in the risk of deep vein
thrombosis (DVT) with tamoxifen treatment comes from the
“National Surgical Adjuvant Breast and Bowel Project-1”12 (NSABP-
1) trial ﬁndings; which showed 35women on tamoxifen developed
DVT compared with just 22 women in the placebo group. The
excess risk appeared greater among women aged 50 years or older.
The relative risk (RR) in this age group was 1.71 (95% CI 0.85e3.58).
For all women in the trial aged 49 years or younger, there were 8
cases recorded in the placebo group versus 11 in the Tamoxifen
group with an RR of 1.39 (95% CI 0.51e3.99) (Table 2).
Table 1
Incidence of symptomatic VTE estimated from HES 2003/04.
Number of patients
with an event
Sample
size
Incidence
Femoral head 237 23,538 1.01%
Knee replacement 493 52,535 0.94%
Vascular 1186 169,218 0.70%
Adult cardiac 208 40,180 0.52%
Hip replacement 293 57,899 0.51%
Transplantation 11 2375 0.46%
Thoracic 117 26,002 0.45%
Lower GI surgery 428 95,968 0.45%
Renal replacement 140 39,733 0.35%
UGI surgery 356 110,562 0.32%
Fractures 555 181,346 0.31%
ITU 1215 448,253 0.27%
Oncology 1311 529,069 0.25%
Radiology Cardiovascular 404 221,317 0.18%
Endoscopic and Percutaneous 2383 1,376,236 0.17%
Joints other 29 17,553 0.17%
Spine 76 56,559 0.13%
Orthopaedic (others) 254 219116 0.12%
Neurosurgery not spine 229 215,533 0.11%
Plastic 259 314,817 0.08%
Urology 121 164,362 0.07%
Hernia 72 115,703 0.06%
Gynaecological 179 443,529 0.04%
Arthroscopy 34 112,123 0.03%
Anus and Piles 26 86,671 0.03%
*Breast 22 78,547 0.03%
ENT 51 209,600 0.02%
Head and Neck 16 80,258 0.02%
Max facial dental 34 184,784 0.02%
Eyes 69 457,382 0.02%
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In the light of established evidence pointing towards increased
VTE risk with tamoxifen and a further increment of this risk with
surgery and recent chemotherapy treatment, stopping tamoxifen
in the perioperative period should be considered as the best safe
practice in high risk cases. Determining safe stoppage duration for
tamoxifen before surgery without worsening the cancer prog-
nosis remains a challenge. In the absence of nationally agreed
guidelines regarding, universally agreed protocols across health
services are difﬁcult to implement. Hence, one assumes that every
hospital follows local protocols in this regard based on theTable 2
Average annual rates of vascular-related events by age at study entry (NSABP-1 trial).
Type of event by
age at entry
No. of events Rate per 1000 women 95% CI
Placebo Tamoxifen Placebo Tamoxifen
Strokea 24 38 0.92 1.45 0.93e2.77
< 49 yrs old 4 3 0.39 0.30 0.11e4.49
>50 yrs old 20 35 1.26 2.20 0.98e3.20
Transient Ischemic
Attack
25 19 0.96 0.73 0.40e1.44
< 49 yrs old 4 3 0.39 0.30 0.11e4.49
>50 yrs old 21 16 1.32 1.01 0.37e1.53
Pulmonary
Embolismb
6 18 0.23 0.69 1.15e9.27
<49 yrs old 1 2 0.10 0.20 0.11e119.62
>50yrs old 5 16 0.31 1.00 1.12e11.15
Deep Vein
Thrombosisc
22 35 0.84 1.34 0.91e2.86
<49 yrs old 8 11 0.78 1.08 0.51e3.99
>50 yrs old 14 24 0.88 1.51 0.85e3.58
a Seven cases were fatal (three in placebo group and four in Tamoxifen group).
b Three cases in Tamoxifen group were fatal.
c All but three cases required hospitalization.individual VTE risk stratiﬁcation and experience of the operating
surgeon; this approach has potential to result in signiﬁcant
practice variations.
The Committee on Safety of Medicines (CSM), an independent
advisory body for UK licensing authorities on safety of prescribing
medicines, have recommended (pharmacovigilance guidance;
2002)16 continuation of tamoxifen therapy before surgery or
following long-term immobility, unless the risk of tamoxifen-
induced thrombosis outweighs the risk of interrupting the treat-
ment in breast cancer patients. In situations warranting treatment
suspension, surgeons are advised to consider cancer stage, grade,
duration and clinical response to therapy at the time of decision
making. However, since this guidance was published, there have
been overwhelming evidence from trials (NSABP-1, EORTC) and
observational studies (The Million Women) linking the pre-
operative use of tamoxifen to an increased risk of VTE following
surgery. This risk remains high up to 12 weeks following in-patient
and up to 6 weeks after day surgery under GA. In the light this and
further new evidence on the heightened risk with recent chemo-
therapy treatment10,11 the old CSM recommendations require
revision. Further, CSM guidance has a potential to be interpreted
and accepted as a generic recommendation in the absence of
patient or procedure exclusion criteria leaving the door open to
some variability in understanding the guidance.
Our proposed algorithm on stoppage durations in the peri-
operative period have been devised taking into consideration all
the above factors and different patient groups. Patient selection
based on VTE risk stratiﬁcation is derived from the National Clinical
Guidelines Centre Group (NCGC) criteria (Table 3). In order to
determine the safe stoppage and restart times of tamoxifen prior to
and after surgery we have considered the pharmacokinetics of the
drug.13 Following administration of a single oral dose of 20 mg of
tamoxifen, the average peak plasma concentration is achieved
within approximately 5 h. Tamoxifen is extensively metabolized to
N-desmethyltamoxifen in the plasma, which has a similar biological
activity to tamoxifen. Chronic administration of 10mg twice daily or
20 mg single dose daily of tamoxifen achieves a steady plasma state
concentration of both tamoxifen and its active metabolite in 4 and 8
weeks period respectively. The decline in plasma concentration
follows a biphasic patternwith an elimination half life of 7e14 days.
Tamoxifen is primarily excreted in faeces with 65% of the
administered dose excreted over a period of 2 weeks. Therefore
approximately 98% of the drug would be fully eliminated from the
plasma by 3 weeks. The decision to restart tamoxifen in the post
operative period is complex and dependent on various factors,
mostly related to patient’s general condition, cancer stage, nature
and duration of surgical procedure performed. The guidance from
NICE on the perioperative risk of VTE from different surgical
operations across various specialities should also be consideredTable 3
VTE Risk Stratiﬁcation Based On The National Clinical Guidelines Centre Group
Criteria.
Active cancer or cancer treatment
Age over 60 years
One or more signiﬁcant medical comorbidities i.e.
Heart disease; metabolic, endocrine or respiratory pathologies
acute infectious diseases; inﬂammatory conditions
Critical care admission
Dehydration
Known thrombophilias
Obesity (BMI over 30 kg/m2)
Personal history or ﬁrst-degree relative with a history of VTE
Use of hormone replacement therapy
Use of oestrogen-containing contraceptive therapy
Varicose veins with phlebitis
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replacement, tamoxifen is stopped for 3 weeks prior and after the
procedure. This time period is determined based on the nature of
surgery (high risk for VTE) and also the duration of rehabilitation.
Generally this period of tamoxifen stoppage is considered
acceptable without any major risk of cancer progression or
recurrence; although conclusive evidence is lacking. The overall
risk of VTE for patients on tamoxifen undergoing breast surgery is
low, following the generic guidance on VTE risk reduction i.e.
using mechanical prophylaxis TED stockings and ﬂowtrons boots
in the peri and post operative period a further minimization of the
risk can be achieved.
Operative duration is a risk factor for VTA. NCGC guidance
recommends the use of pharmacological thrombo prophylaxis for
general surgical procedures lasting more than 90 min or limb and
pelvic surgeries lasting more than 60 min. There is no reported
evidence considering ASA grade in itself as an independent risk
factor for VTE, although recovery times are known to be longer in
higher ASA grade elderly patients following surgery.17 This on its
own can be a signiﬁcant risk factor for post operative VTE, therefore
thrombo prophylaxis in such patient groups should be considered
even after a low risk surgical procedure.4. Conclusion
Tamoxifen treatment interruption may be required prior to
some surgical procedures. There are no deﬁnitive guidelines on the
duration of stopping medication pre and post operatively. We
thereforewould like to propose a framework of guidelines based on
the best available evidence from clinically relevant studies and
pharmacological evidence. Our proposed guidelines are summa-
rized in the ﬂow chart below.
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